Development of a unique Bismuth (Bi-213) automated generator for use in cancer therapy.

被引：0
|
作者：
Bray, LA [1 ]
Tingey, JM [1 ]
DesChane, JR [1 ]
Egorov, OB [1 ]
机构：
[1] Pacific NW Natl Lab, Richland, WA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 1998年 / 216卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
049-IEC
引用
收藏
页码：U927 / U927
页数：1
相关论文
共 50 条
  • [21] Development of antiangiogenic radioligands for cancer in imaging and therapy.
    Scappaticci, FA
    Goris, M
    Contreras, A
    Trisler, K
    Nolan, GP
    BLOOD, 2000, 96 (11) : 61B - 61B
  • [22] Protocadherin-PC: A unique molecular target for prostate cancer therapy.
    Buttyan, R
    Chen, MW
    Yang, XZ
    Vacherot, F
    Terry, S
    Benson, MC
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9141S - 9141S
  • [23] Prospects for the Development of an 225Ac/213Bi Generator Using Inorganic Hydroxide Sorbents
    Betenekov, N. D.
    Denisov, E., I
    Vasiliev, A. N.
    Ermolaev, S., V
    Zhuikov, B. L.
    RADIOCHEMISTRY, 2019, 61 (02) : 211 - 219
  • [24] Prospects for the Development of an 225Ac/213Bi Generator Using Inorganic Hydroxide Sorbents
    N. D. Betenekov
    E. I. Denisov
    A. N. Vasiliev
    S. V. Ermolaev
    B. L. Zhuikov
    Radiochemistry, 2019, 61 : 211 - 219
  • [25] Development and application of radiopharmaceuticals designed to monitor cancer therapy.
    Welch, MJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U2 - U2
  • [26] Preclinical development of interleukin-18 for cancer therapy.
    Zdenka, LJ
    Ho, YS
    Trulli, S
    McCabe, FL
    Maier, C
    Kirkpatrick, R
    Elefante, L
    Chen, YJ
    Herzyk, D
    Johanson, K
    Rose, M
    Whitacre, M
    Abdel-Meguid, SS
    Randall, KJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3806S - 3806S
  • [27] Development of antibody-endostatin fusion proteins for cancer therapy.
    Shin, S
    Cho, H
    Kim, H
    Iruela-Arispe, M
    Penichet, ML
    Morrison, SL
    Rosenblatt, JD
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3666S - 3666S
  • [28] Preclinical development of SHetA2 for endometrial cancer therapy.
    Chandra, Vishal
    Rai, Rajani
    Benbrook, Doris M.
    CLINICAL CANCER RESEARCH, 2021, 27 (03)
  • [29] Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
    Mulford, DA
    Pandit-Taskar, N
    McDevitt, MR
    Finn, RD
    Weiss, MA
    Apostolidis, C
    Morgenstern, A
    Divgi, CR
    Larson, SM
    Scheinberg, DA
    Jurcic, JG
    BLOOD, 2004, 104 (11) : 496A - 496A
  • [30] Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer - a pilot study
    Scheidhauer, K.
    Seidl, C.
    Bruchertseifer, F.
    Apostolidis, C.
    Autenrieth, M.
    Kurtz, F.
    Horn, T.
    Schwaiger, M.
    Gschwend, J.
    D'Alessandria, C.
    Pfob, C.
    Senekowitsch-Schmidtke, R.
    Morgenstern, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S130 - S130
12345